Sunday 15 November 2026
Export DYAI’s income statement to Excel — free account
Dyadic International Inc.
DYAIDyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
- Revenue
- −61.4%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +0.80%
Quarter to September 2026, against a year earlier
0.33
0.02
−5.71%
Follow DYAI
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | +20.1% | 7 | 13 | 17 | +75.7% | |
| Gross margin, % | 100.00 | 10.31 | 20.70 | 13.17 | 11.05 | 19.11 | 27.54 | 31.84 | 65.82 | 24.93 | 17.85 | (75.1) pt | ||||||
| EBT | 1 | (2) | (7) | (8) | (9) | (13) | (10) | (7) | (6) | (7) | (7) | n/m | ||||||
| EBT margin, % | 100.00 | (290.41) | (517.01) | (493.59) | (580.19) | (543.73) | (332.23) | (234.42) | (166.20) | (238.31) | (226.87) | (338.3) pt | ||||||
| Net income | 0 | (2) | (6) | (8) | (9) | (13) | (10) | (7) | (6) | (7) | (7) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.02 | 0.03 | 0.05 | 0.06 | 0.06 | 0.09 | 0.10 | 0.10 | 0.12 | 0.09 | 0.08 | +21.7% | |||||
| Earnings | (0.10) | (0.07) | (0.21) | (0.31) | (0.34) | (0.47) | (0.34) | (0.24) | (0.20) | (0.23) | (0.21) | +9.7% | ||||||
| Cash flow | (0.17) | (0.06) | (0.16) | (0.21) | (0.24) | (0.41) | (0.28) | (0.23) | (0.14) | (0.17) | (0.18) | +0.6% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.17) | (0.06) | (0.16) | (0.21) | (0.24) | (0.41) | (0.28) | (0.23) | (0.14) | (0.17) | (0.18) | +0.6% | ||||||
| Book value | 1.58 | 1.73 | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | 0.20 | 0.08 | 0.04 | (0.07) | (33.9%) | ||||||
| Shares, m | 37 | 29 | 28 | 27 | 27 | 28 | 28 | 29 | 29 | 33 | 36 | (1.3%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 63.08 | 40.39 | 83.21 | 92.26 | 52.35 | 13.36 | 15.80 | 14.68 | 9.92 | 3.97 | 38.5 | ||||||
| P/B | 0.00 | 0.96 | 1.23 | 3.90 | 5.20 | 6.84 | 3.53 | 7.79 | 20.77 | 24.88 | 0.00 | 7.5 | ||||||
| EV/Sales | (8.35) | 0.25 | 8.57 | 62.85 | 74.10 | 43.92 | 9.04 | 13.33 | 13.45 | 8.78 | 4.09 | 22.6 | ||||||
| EV/FCF | 0.00 | (0.15) | (2.46) | (17.93) | (17.76) | (9.27) | (3.23) | (5.65) | (11.51) | (4.67) | (1.77) | (7.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (6) | (2) | (4) | (6) | (7) | (11) | (8) | (7) | (4) | (6) | (7) | (0.6%) | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | (6) | (2) | (4) | (6) | (7) | (11) | (8) | (7) | (4) | (6) | (7) | (0.6%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 57 | 49 | 42 | 34 | 28 | 18 | 11 | 6 | 7 | 6 | 3 | (21.8%) | |||||
| Net debt | (56) | (48) | (41) | (34) | (29) | (20) | (13) | (7) | (4) | (4) | 0 | (26.5%) | ||||||
| Shareholders’ equity | 58 | 50 | 42 | 36 | 28 | 18 | 11 | 6 | 2 | 1 | (3) | (34.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 0.00 | (8.42) | (12.10) | (20.58) | (27.62) | (50.89) | (55.61) | (61.97) | (64.01) | (74.11) | (71.43) | (74.1) pt | |||||
| ROIC | 26.74 | 20.70 | (380.11) | (353.37) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (26.7) pt | ||||||
| ROE | (12.14) | (3.97) | (12.32) | (21.22) | (29.00) | (55.81) | (66.05) | (80.11) | (139.16) | (397.80) | (47,310.78) | (385.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 5 | — | (2.6%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.22 | 0.28 | 0.27 | 0.34 | 0.42 | 0.41 | 0.58 | 0.62 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 13 Nov 2026
Dyadic International Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALLR Allarity Therapeutics, Inc. | $14.5M | — (loss-making) | — (loss-making) | — | n/m | +15.63% (above 0%: growing) | 100.00% | (110,140.00%) | Compare |
| NCEL NewcelX Ltd. | $14.5M | — (loss-making) | — | — | — | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| QNTM Quantum Biopharma Ltd. | $14.4M | — (loss-making) | — (loss-making) | — | n/m | +5.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MCRB Seres Therapeutics, Inc. | $14.4M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −574.29% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| DYAI Dyadic International Inc. | $14.0M | — (loss-making) | — (loss-making) | −61.44% (below 0%: shrinking) | n/m | +19.88% (above 0%: growing) | 16.47% | (403.55%) | |
| NEUP Neuphoria Therapeutics Inc. | $14.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $14.0M | — (loss-making) | — (loss-making) | +287.18% (above 0%: growing) | n/m | +105.40% (above 0%: growing) | 100.00% | (762.98%) | Compare |
| LSTA Lisata Therapeutics, Inc. | $13.8M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PLUR Pluri Inc. | $13.7M | — (loss-making) | — (loss-making) | +140.19% (above 0%: growing) | n/m | +18.00% (above 0%: growing) | 55.34% | (2,051.25%) | Compare |
| Median of peers | $14.2M | — | — | +68.95% | — | +16.82% | 100.00% | (762.98%) |
Pay and ownership Proxy statement filed 12 May 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.01m | 518.55k | 76.42 |
| 2024 | 1.04m | 1.08m | 39.77 |
| 2023 | 1.04m | 1.11m | 29.93 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement
Dyadic International Inc. (DYAI) Latest News
What happened
- Results Dyadic reported third-quarter revenue of $449,101, down 61% year over year, and a $1.36 million net loss.
- Product Dyadic’s C1-produced RSV and malaria antibodies advanced into mouse pharmacokinetic studies comparing them with CHO-produced versions.
- Deal Dyadic, BRIG BIO and Strive Nutrition agreed to develop precision-fermented alpha-lactalbumin, targeting initial supply above 10 metric tonnes.
- How One Biotech Stock Is Trying To Reduce A Big Hidden Cost Simply Wall St.
- Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... transcript
- Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
- Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
- An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets TMX Newsfile
- Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
- Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development GlobeNewswire
- Dyadic International Inc (DYAI) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... GuruFocus.com
- Transcript: Dyadic International Q1 2026 Earnings Conference Call Benzinga transcript
- Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress GlobeNewswire
17 more headlines
- Dyadic: 3 Key Takeaways for Long-Term Investors The Motley Fool
- Dyadic International (DYAI) Q2 2026 Earnings Call Transcript The Motley Fool transcript
- DYAI: Second Quarter Results
- Dyadic International, Inc. Q2 2026 Earnings Call Summary Moby
- Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
- Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
- Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
- Dyadic Expands IP Protection and Business Development Activities in Japan
- Dyadic (DYAI) Q1 2026 Earnings Call Transcript The Motley Fool transcript
- DYAI: First Quarter Results Zacks Small Cap Research
- Dyadic International, Inc. Q1 2026 Earnings Call Summary Moby
- DYAI: Introducing AlbuFree DX Zacks Small Cap Research
- Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long Simply Wall St.
- Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... GuruFocus.com
- Dyadic International, Inc. Q4 2025 Earnings Call Summary Moby
- Dyadic (DYAI) Q4 2025 Earnings Call Transcript The Motley Fool transcript
- Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress